Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.70 USD
Change Today +0.03 / 4.48%
Volume 249.1K
DSCO On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

discovery laboratories inc (DSCO) Snapshot

Open
$0.65
Previous Close
$0.67
Day High
$0.73
Day Low
$0.65
52 Week High
07/7/14 - $2.03
52 Week Low
06/29/15 - $0.64
Market Cap
60.0M
Average Volume 10 Days
342.5K
EPS TTM
$-0.51
Shares Outstanding
85.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DISCOVERY LABORATORIES INC (DSCO)

Related News

No related news articles were found.

discovery laboratories inc (DSCO) Related Businessweek News

No Related Businessweek News Found

discovery laboratories inc (DSCO) Details

Discovery Laboratories, Inc., a specialty biotechnology company, focuses on developing products for critical-care patients with respiratory disease and improving care in pulmonary medicine. Its proprietary drug technology produces a synthetic peptide-containing surfactant (KL4 surfactant in liquid, lyophilized, and aerosolized dosage forms), as well as develops drug delivery technologies to enable efficient delivery of its aerosolized KL4 surfactant. The company offers SURFAXIN Intratracheal suspension for the prevention of respiratory distress syndrome (RDS) in premature infants; AFECTAIR device, a disposable aerosol-conducting airway connector for infants; and WARMING CRADLE, a dry-block heating device that is designed to warm drug vials at the same temperature that is designated in the SURFAXIN prescribing information. It is also developing AEROSURF, a drug/device combination product that delivers KL4 surfactant in aerosolized form using the lyophilized KL4 surfactant is in Phase II clinical trials for the treatment of RDS in premature infants. In addition, the company is developing a lyophilized (freeze-dried) dosage form of its KL4 surfactant. The company has a collaboration agreement with Battelle Memorial Institute for the development and commercialization of AEROSURF; and a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.

58 Employees
Last Reported Date: 05/11/15
Founded in 1992

discovery laboratories inc (DSCO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $253.5K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $303.5K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $186.4K
Compensation as of Fiscal Year 2014.

discovery laboratories inc (DSCO) Key Developments

Discovery Labs Receives Nasdaq Notification Related To Minimum Bid Price

Discovery Laboratories, Inc. announced that, on June 29, 2015, the Company received a letter from The Nasdaq Stock Market indicating that, because the Company's common stock has not maintained a minimum closing bid price of $1.00 per share over the previous 30 consecutive business days, the Company is no longer in compliance with Nasdaq's Listing Rule 5550(a)(2). This notice of noncompliance has no immediate impact on the continued listing or trading of the Company's common stock on the Nasdaq Capital Market. Under the Nasdaq Listing Rules, the Company has 180 calendar days ("grace period"), or until December 28, 2015, to regain compliance with the Minimum Bid Price Requirement. If during the grace period, the Company's common stock achieves a minimum closing bid price of at least $1.00 per share for a period of at least ten consecutive business days, the Company will regain compliance with the Minimum Bid Price Requirement and its common stock will continue to be eligible for listing on the Nasdaq Capital Market. If the Company does not achieve compliance with the Minimum Bid Price Requirement during the grace period, Nasdaq will provide written notification to the Company that its common stock is subject to delisting. However, if on the last day of the grace period, the Company complies with the market value requirement for continued listing and all other listing standards for initial listing on the Nasdaq Capital Market, and indicates its intention to cure its non-compliance with the Minimum Bid Price Requirement, the Company may be eligible for an additional grace period through June 27, 2016. The Company intends to monitor the closing bid price of its common stock and, if appropriate, consider available options potentially to regain compliance with the Minimum Bid Price Requirement under the Nasdaq Listing Rules.

Discovery labs Presents at BIO International Convention 2015, Jun-18-2015 02:00 PM

Discovery labs Presents at BIO International Convention 2015, Jun-18-2015 02:00 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States.

Discovery Laboratories Inc. Announces Encouraging Data from Phase IIa RDS trial

Discovery Laboratories Inc. has announced encouraging data from AEROSURF Phase IIa clinical trial in premature infants with respiratory distress syndrome, or RDS. Key objectives of the study were achieved, including the primary objective of demonstrating the safety and tolerability of a single exposure of aerosolized KL4 surfactant administered in three escalating inhaled doses to premature infants 29 to 34 week gestational age and receiving nasal continuous positive airway pressure (nCPAP) for RDS, compared to infants receiving nCPAP alone, and establishing proof of concept for the Company's proprietary technology platform based on physiological data suggesting that aerosolized KL4 surfactant is being delivered into the lung of premature infants, and acceptable performance of the novel capillary aerosol generator (CAG) technology in the neonatal intensive care unit (NICU).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSCO:US $0.70 USD +0.03

DSCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.41 USD -0.11
AbbVie Inc $68.21 USD -0.30
View Industry Companies
 

Industry Analysis

DSCO

Industry Average

Valuation DSCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 20.0x
Price/Book 7.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DISCOVERY LABORATORIES INC, please visit www.discoverylabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.